CAMBRIDGE, Mass. and WINNERSH, U.K., May 8, 2007 (PRIME NEWSWIRE) -- Biogen Idec (Nasdaq:BIIB) and Vernalis plc (Nasdaq:VNLS) (LSE:VER) today announced the initiation of the Phase II program of BIIB014 (also known as V2006), an oral compound, for the treatment of Parkinson's disease. BIIB014 is an adenosine A2A receptor antagonist that may offer a non-dopaminergic therapy for patients with Parkinson's disease.
